GSK announced that the European Commission has approved Exdensur (depemokimab) [...]
electronRx will launch its pDx app at the HLTH 2025 [...]
Ethris has dosed the first patient in a Phase 2a [...]
Qureight’s deep-learning biomarkers confirm representativeness of Insilico’s Phase 2a IPF [...]
Partnership further validates Ethris’ novel technology platform based on stabilized [...]